An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma

Cocks, Kim; Cohen, Dena; Wisløff, Finn; Sezer, Orhan; Lee, S; Hippe, Erik; Gimsing, Peter; Turesson, Ingemar; Hájek, Roman; Smith, Alastair G.; Graham, Liz; Phillips, Andrew T.; Stead, Maxine; Velikova, Galina; Brown, Julia

doi:10.1016/j.ejca.2007.04.022

Cited by 206 publications

(197 citation statements)

References 6 publications

Supporting

Mentioning

182

Contrasting

Unclassified

Order By: Relevance

“…15 Each questionnaire takes approximately 10-15 min to complete. 16 The QLQ-C30 includes 5 functional domains (Physical Functioning, Emotional Functioning, Cognitive Functioning, Social Functioning, and Role Functioning), where a higher score indicates better function.…”

Section: Design and Methodsmentioning

confidence: 99%

“…At the time this study was initiated, the 24-item QLQ-MY24 was in development, and 4 questions regarding social support were removed during validation, resulting in the validated QLQ-MY20. 15 For consistency, the QLQ-MY24 form was administered throughout this study, but the 4 questions removed during validation were omitted from the analysis.…”

Section: Design and Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial

Dimopoulos

Delforge²,

Hájek

et al. 2012

Haematologica

Self Cite

View full text Add to dashboard Cite

The MM-015 trial assessed the effect of lenalidomide-based therapy on health-related quality of life. Patients (n=459) with newly diagnosed multiple myeloma aged 65 years or over were randomized 1:1:1 to nine 4-week cycles of lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance; or lenalidomide, melphalan, and prednisone, or melphalan and prednisone, with no maintenance therapy. Patients completed health-related quality of life questionnaires at baseline, after every third treatment cycle, and at treatment end. Health-related quality of life improved in all treatment groups during induction therapy. Patients receiving lenalidomide maintenance had the most pronounced improvements, Global Health Status/Quality of Life (P<0.05), Physical Functioning (P<0.01), and Side Effects of Treatment (P<0.05) out of 6 pre-selected health-related quality of life domains. More patients receiving lenalidomide maintenance achieved minimal important differences (P<0.05 for Physical Functioning). Therefore, lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in patients with newly diagnosed multiple myeloma. (Clinicaltrials.gov identifier NCT00405756). ABSTRACTLenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older:

show abstract

Section: Design and Methodsmentioning

confidence: 99%

Section: Design and Methodsmentioning

confidence: 99%

Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial

Dimopoulos

Delforge²,

Hájek

et al. 2012

Haematologica

Self Cite

View full text Add to dashboard Cite

show abstract

“…[26][27][28][29][30][31][32][33][34][35] These questionnaires were administered in paper format at the hospital. Patients completed the questionnaires at several time points: baseline; at the end of Cycle 1 (after 4 weeks of treatment with Rd and after 6 weeks of treatment with MPT); after 3, 6, 12, and 18 months of treatment; and at study discontinuation.…”

Section: Hrqol Assessmentsmentioning

confidence: 99%

Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide

et al. 2015

View full text Add to dashboard Cite

The randomized pivotal phase III FIRST trial (Frontline Investigation of lenalidomide/dexamethasone [Rev/Dex] versus Standard Thalidomide; IFM 2007-01/ MM-020; clinicaltrials.gov identifier: 00689936; EudraCT No. 2007-004823-39) compared the efficacy and safety of Rd, administered continuously until progressive disease (PD) or for a fixed 18-month duration (Rd18), with MPT given for 18 months in NDMM patients who were aged 65 years or over, or who were aged under 65 years and ineligible for stem cell transplantation. Continuous Rd showed improved progression-free survival (PFS) and overall survival (OS) benefit at interim analysis compared with MPT. 19 Although extending survival is clearly the ultimate treatment ©2015 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2014 The online version of this article has a Supplementary Appendix. Manuscript received on November 14, 2014. Manuscript accepted on March 6, 2015 We compared the health-related quality-of-life of patients with newly diagnosed multiple myeloma aged over 65 years or transplant-ineligible in the pivotal, phase III FIRST trial. Patients received: i) continuous lenalidomide and low-dose dexamethasone until disease progression; ii) fixed cycles of lenalidomide and low-dose dexamethasone for 18 months; or iii) fixed cycles of melphalan, prednisone, thalidomide for 18 months. Data were collected using the validated questionnaires (QLQ-MY20, QLQ-C30, and EQ-5D). The analysis focused on the EQ-5D utility value and six domains pre-selected for their perceived clinical relevance. Lenalidomide and low-dose dexamethasone, and melphalan, prednisone, thalidomide improved patients' health-related quality-of-life from baseline over the duration of the study across all pre-selected domains of the QLQ-C30 and EQ-5D. In the QLQ-MY20, lenalidomide and low-dose dexamethasone demonstrated a significantly greater reduction in the Disease Symptoms domain compared with melphalan, prednisone, thalidomide at Month 3, and significantly lower scores for QLQ-MY20 Side Effects of Treatment at all post-baseline assessments except Month 18. Linear mixed-model repeatedmeasures analyses confirmed the results observed in the cross-sectional analysis. Continuous lenalidomide and low-dose dexamethasone delays disease progression versus melphalan, prednisone, thalidomide and has been associated with a clinically meaningful improvement in health-related quality-of-life. These results further establish continuous lenalidomide and low-dose dexamethasone as a new standard of care for initial therapy of myeloma by demonstrating superior health-related quality-of-life during treatment, compared with melphalan, prednisone, thalidomide.Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide [20][21][22][23] In this population, treatment objectives should be to improve disease management by delaying disease progression, optimizing re...

show abstract

“…The EORTC QLQ-MY24 questionnaire measures specific aspects that are relevant for the quality of life (QoL) in multiple myeloma patients. The questionnaire contains the following scales: pain, side effects of treatment, social support, body image and future perspectives [13].…”

Section: Hrqol Questionnairesmentioning

confidence: 99%

Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial

et al. 2011

View full text Add to dashboard Cite

Thalidomide with melphalan/prednisone (MPT) was defined as standard treatment in elderly patients with multiple myeloma (MM) based on five randomized trials. In one of these trials, HOVON49, a prospective health-related quality-of-life (HRQoL) study was initiated in order to assess the impact of thalidomide on QoL. Patients aged >65 years with newly diagnosed MM were randomized to receive melphalan plus prednisone (MP) or MPT, followed by thalidomide maintenance in the MPT arm. Two hundred eighty-four patients were included in this side study (MP, n= 149; MPT n=135). HRQoL was assessed with the EORTC Core QoL Questionnaire (QLQ-C30) and the myelomaspecific module (QLQ-MY24) at baseline and at predetermined intervals during treatment. The QLQ-C30 subscales physical function (P=0.044) and constipation (P<0.001) showed an improvement during induction in favour of the

show abstract

An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma

Cited by 206 publications

References 6 publications

Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial

Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial

Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide

Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial

Contact Info

Product

Resources

About